Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPAB Back In The Spotlight As Repeal Bill Clears House Subcommittee

This article was originally published in The Pink Sheet Daily

Executive Summary

House Energy and Commerce health panel votes to repeal IPAB; Ways and Means Committee plans a hearing in early March.

You may also be interested in...



CMS Budget Plan: $1 Bil. Increase For Administrative Activities Is New, But Drug Policy Proposals Are Old

CMS budget plan reprises Medicare drug rebates for dual eligibles, eliminating brand/generic patent settlements and other unsuccessful Rx proposals.

IPAB Members Will Be Named In Time To Begin Recommendations In 2014, Sebelius Says

The White House has begun discussions with potential board member nominees, HHS secretary tells House Energy and Commerce Health Subcommittee.

Insulin Report Revives Senate Finance Committee Push On Drug Pricing Legislation

Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel